Switzerland· 59377001
OLIMEL 4,4 % ohne Elektrolyte, Infusionslösung
A lösungen zur parenteralen ernährung, kombinationen product, registered in Switzerland by Baxter AG and dispensed under Swissmedic category B. The same ATC class is registered in 11 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Lösungen zur parenteralen ernährung, kombinationen is registered in 11 of 19 countries.
Countries holding a registration under ATC B05BA10 (lösungen zur parenteralen ernährung, kombinationen), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 7 of them publish a price we can compare per daily dose
Lösungen zur parenteralen ernährung, kombinationen · ATC B05BA10
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Swissmedic (Switzerland)- Manufacturer
- Baxter AG
- Country
- Switzerland (CH)
- ATC code
- B05BA10
- ATC class
- Lösungen zur parenteralen Ernährung, Kombinationen
- Swissmedic category
- B
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
6 interactions on record for lösungen zur parenteralen ernährung, kombinationen.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lösungen zur parenteralen ernährung, kombinationen · interactions on record
6 records
- 2 severe
- 4 moderate
Most severe, free to view
- ErdafitinibL01EN01severe
- ErdafitinibL01EX16severe
- AmfetamineN06BA01moderate
- DexamfetamineN06BA02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under B05BA10
Lösungen zur parenteralen ernährung, kombinationen, as other registers publish it.
- PolandAminomel 10 EBaxter Polska Sp. z o.o.
- PolandAminomel 12,5 EBaxter Polska Sp. z o.o.
- PolandAminomel NephroBaxter Polska Sp. z o.o.
- BelgiumAminomix 1 NovumFresenius Kabi
- CzechiaAMINOMIX 1 NOVUMFresenius Kabi Deutschland GmbH, Bad Homburg
- CzechiaAMINOMIX 1 NOVUMFresenius Kabi Deutschland GmbH, Bad Homburg
- CzechiaAMINOMIX 1 NOVUMFresenius Kabi Deutschland GmbH, Bad Homburg
- NetherlandsAminomix 1 Novum, oplossing voor infusieFresenius Kabi Nederland B.V.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e853c836-0981-4597-93ef-c55e2beec71b GET /v1/drugs/e853c836-0981-4597-93ef-c55e2beec71b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Synthetika"
}See everything about lösungen zur parenteralen ernährung, kombinationen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.